<b><em>Doyle v. Reata Pharmaceuticals, Inc</em>.,</b><br /> No. 21-cv-00987 (E.D. Tex.).
| Lead Plaintiff Deadline: | Lead Plaintiff Deadline:01/01/1900 |
| Status: | Status:Settled |
| Court: | Court:Eastern District of Texas |
| Case Number: | Case Number:21-cv-00987 |
Kirby McInerney announced a proposed $45 million classwide settlement on behalf of investors in Reata Pharmaceuticals Inc. Plaintiffs alleged that Reata Pharmaceuticals made false and/or misleading statements—including in connection with its secondary public stock offerings—concerning, inter alia, the FDA guidance regarding the design of its clinical trial (CARDINAL) for its drug candidate, bardoxolone methyl. When the FDA revealed serious concerns that it had previously raised to Reata, the share price declined materially.
Copies of the Settlement Notice and Proof of Claim Form can be viewed under the Resources section of this page. The Proof of Claim Form must be submitted no later than April 24, 2024. Additional documents, information, and important dates can be found here: Reata Securities Settlement.
Copies of the Settlement Notice and Proof of Claim Form can be viewed under the Resources section of this page. The Proof of Claim Form must be submitted no later than April 24, 2024. Additional documents, information, and important dates can be found here: Reata Securities Settlement.